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doi:10.1016/j.ejvs.2010.03.012Abstract Objectives: The search for markers predicting risk of plaque rupture in carotid
atherosclerosis is still ongoing. Previous findings showed that pregnancy-associated plasma
protein-A (PAPP-A) levels correlate with an adverse plaque morphology. However, the role
of PAPP-A in plaque destabilisation is still uncertain.
Material and methods: Patients with carotid artery stenosis involved in the study were asymp-
tomatic (nZ 29) and symptomatic (nZ 37). Carotid plaques were characterised by histology
(nZ 33). Immunohistochemistry (nZ 17) was used to determine expression of PAPP-A and
CD68 within the plaques. Serum levels of PAPP-A were measured by the enzyme-linked immu-
nosorbent assay (ELISA).
Results: Circulating PAPP-A levels were significantly higher in patients with unstable versus
stable plaques (0.10 0.06 vs. 0.07 0.04 mg ml1, pZ 0.047) and interestingly, in asymptom-
atic versus symptomatic patients (0.11  0.05 vs. 0.069  0.09 mg ml1, pZ 0.025). These
differences remained statistically significant after adjustment for age, gender and degree of
stenosis (pZ 0.050). PAPP-A expression in plaques correlated significantly with CD68 positive
macrophages, cap-thickness and its serological values (rZ þ0.291, p< 0.001, rZ 0.639,
p< 0.001 and rZ 0.618, p< 0.008, respectively). Furthermore, PAPP-A serum values demon-
strated a significant positive predictive value of 68.8% for unstable plaques.and Endovascular Surgery, Isar Medical Center, Sonnenstr. 24-26, D-80331 Munich, Germany. Tel.: þ49
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ine.de (P. Heider).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
PAPP-A and Carotid Plaque Activity 669Table 1 Presentation of the num
Asymptomatic pat.
Serology 29
Histology 15
ICH 9Conclusion: Our present data confirmed the close relationship betweenexpression of PAPP-A and
plaque instability and furthermore correlated significantly with cap thickness. However, the
question whether PAPP-A is a useful predictive marker of plaque instability remains unresolved.
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embolus originating from formation of a platelet-rich
thrombus superimposed on atherosclerotic plaque or by
plaque rupture in the carotid artery. Conventional risk
factors often fail to identify patients with rupture-prone
plaques at high risk of an impending stroke. It has been
recognised that plaque properties other than size and
degree of stenosis are important for the identification of
patients at high risk of cerebral ischaemic events. This
applies in particular to unstable plaques.1 New concepts on
pathophysiology of plaque vulnerability and rupture have
been recently established and have contributed to a better
understanding of the molecular and cellular mechanisms
involved.2 New markers of atherosclerotic plaque devel-
opment and activity are believed to identify patients at
high risk of impending stroke among which the pregnancy-
associated plasma protein A (PAPP-A) is an interesting
candidate.3 Recently, peripheral blood levels of PAPP-A
have been proposed as a possible biological marker of
acute coronary syndromes.4 Furthermore, some biochem-
ical and imaging studies have revealed PAPP-A as a factor
that may reflect a high risk of vulnerability.3,4 For example,
Bayes-Genis demonstrated a correlation between plasma
concentration and plaque stability in coronary arteries. We
hypothesised that PAPP-A may be also involved in the
transformation from a stable to an unstable plaque in
carotid artery stenosis (CS).
In our study, we therefore examined circulating blood
levels of PAPP-A in patients with symptomatic and asymp-
tomatic carotid artery stenosis. Furthermore, we evaluated
the relationships between circulating PAPP-A, expression of
PAPP-A in the diseased carotid artery and plaque stability.
Material and Methods
Patient population
The groups of this prospective study consisted of 29
consecutive patients with high-degree asymptomatic
carotid artery stenosis (mean SD age, 67.9 8.2 years,
male 21, female eight), and 37 consecutive patients with
clinically symptomatic carotid artery stenosis (mean SD
age, 68.1 8.6 years, male 25, female 12) scheduled for
carotid thrombendarterectomy (Table 1). Stenosis was
evaluated by colour-coded duplex sonography following.
European Carotid Surgery Trial (ECST) criteria.5 Stenosis
was considered as symptomatic if the patient hadbers of patients.
Symptomatic pat. Total
37 66
18 33
8 17experienced an ipsilateral ocular or cerebral (permanent or
transient) ischaemic event within 6 weeks prior to endar-
terectomy. Carotid endarterectomies were performed by
experienced surgeons during a 9-month period. All patients
underwent detailed neurological examination within 2 days
before operation to discriminate between asymptomatic
and symptomatic carotid artery disease.
All patients with severe carotid artery stenosis (>70% in
asymptomatic and 60% in symptomatic patients) according
to recent American Heart Association (AHA) Recommenda-
tions and a complete three-dimensional plaque suitable for
histological examination after the surgical procedure were
included in the study.
Exclusion criteria included any kind of acute infectious
diseases within the last 6 weeks, advanced liver or kidney
failure, myocardial infarction, unstable or chronic stable,
effort-induced angina of at least 6 months duration accom-
paniedbyevidenceof severecoronaryarterydisease,cardiac
catheter intervention and history of major trauma and
cardiac or general surgery and peripheral arterial occlusive
disease (rest pain or gangrene) within the last 6 months.
The study was performed according to the Guidelines of
the World Medical Association Declaration of Helsinki and
written and informed consent was obtained from all
patients. The study was approved by the Review Board
Committee of the Interdisciplinary Center for Vascular
Diseases of the Technical University of Munich.
Laboratory analysis
Blood samples were obtained at the time of admission to
the vascular surgery unit from an antecubital vein. All
samples were analysed according to the results of Pai, who
investigated the stability of novel plasma markers at
different time points from specimen collection until pro-
cessing.6 Blood serum samples of each patient were frozen
within 2 h after collection.
PAPP-A levels in plasma were determined by means of
a solid phase enzyme-linked immunosorbent assay (ELISA;
Biosource Europe, Nivelles, France) based on the sandwich
principle with analytical sensitivity of <0.19 mg ml1 and
intra-assay/interassay coefficients of variation of 4.08% and
6.39%, respectively. This kit uses a microplate with wells
coated with polyclonal anti-PAPP-A antibody.
An ELISA reader (Dynatech Laboratories, USA) set to
450 nm with wavelength correction set to 620 nm deter-
mined optical density. All standard biochemistry measure-
ments were carried out by the Biochemistry Department at
our institution using standard methods.
Histology/immunohistochemistry
For histological analyses and immunohistochemistry (IHC),
33 patients (15 asymptomatic and 18 symptomatic) and 17
670 P. Heider et al.patients (nine asymptomatic and eight symptomatic) were
included, respectively.
Carotid plaques were removed en bloc during surgery to
preserve the entire plaque structure. Plaques were subse-
quently cut into serial cross sections, starting at the site of
the bifurcation area up to the end of the stenosis. A
representative section for further analysis was defined as
the area with the highest degree of lumen stenosis. Within
this area, four consecutive sections were taken for analysis
from each patients’ sample to avoid accidental results.
IHC was performed on sections (2e3 mm) of formalin-fixed
and paraffin-embedded plaqueetissue samples. Paraffin
sections were first dewaxed with xylene and rehydrated in
descending ethanol sequence (100e70%). Plaque tissue
sections were then routinely stained with haematoxylin and
eosin (HE) and Elastin van Gieson (EvG) to assess tissue struc-
ture of all plaque samples, cellular composition, degree of
infiltration with inflammatory cells, plaque rupture, intra-
plaque haemorrhage, atheroma-associated foam cells and
atheroma-associated macrophages. For IHC, dewaxed and
hydrated tissue section samples were treated with boiling to
retrieve epitopes of appropriate antigens,washed and treated
with appropriate antibodies (PAPP-A, polyclonal rabbit anti-
human, dilution 1:200, anti-CD68, clone KP1, dilution 1:2000,
Dako, Hamburg, Germany) to characterise cellular compo-
nents of cross sections and to detect expression of PAPP-A.
An experiencedpathologist blinded to sample identity and
symptoms graded cross sections for histological features
associated with plaque vulnerability. Histological character-
isation of stable and unstable plaques was performed based
on the already-established and published methods of the
modifiedAHAscheme.7Colocalisation studies formacrophage
foam-cells were performed at serial sections using antibodies
against CD68 antigen and PAPP-A. A quantitative analysis was
performed by measuring areas of PAPP-A-positive cells in
relation to areas of CD68-positive cells as well as to the total
cross section area. SigmaScan 4.0 (Systat Software Inc., San
Jose, USA) was used for measurement of areas of expression.
Finaldatawere thencalculatedasareasofPAPP-expressione
plaque area e ratio (% of plaque area in mm2).Statistical analysis
Values of continuous variableswere expressed asmean SD.
Groups were compared by ManneWhitney U-test for not
normally distributed variables or matched signed-rank test.
Correlations between continuous variables were calculated
using Spearman’s rank correlation coefficients. All testswere
considered significant at the 0.05 level.
Values of PAPP-A, which were not normally distributed,
were presented as medians and ranges and were compared
among the groups with the KruskaleWallis test. In case of
significant differences between the groups, pair wise group
comparison was performed usingWilcoxon rank-sum testing.
Receiver operator characteristic (ROC) curves and the size
of the area under ROC curve (AUC) were applied for the
evaluation of the diagnostic accuracy of PAPP-A in patients
with carotid artery stenosis. AUC> 0.9 indicates the highest
diagnostic accuracy, 0.65e0.9 confident diagnostic utility
and 0.5e0.65 low diagnostic accuracy. Areas under ROC
curves for different tests were compared on the basis oftheir confidence intervals and the U-test. ROC analysis also
allowed determination of specificity and sensitivity (HSS) of
PAPP-A. The optimal decision rule (cut-off point) for
prediction of neurological symptoms was determined by the
Youden index (JZmaximum {sensitivityþ specificity 1})
for each factor and their combinations. Adjustment for age,
gender and degree of stenosis was performed using a linear
regression model to estimate the coefficients of the linear
equation for each factor of adjustment. All analyses were
performed with SPSS 16.0 (SPSS Inc. Chicago, IL, USA).
Results
Clinical data
In this study, we evaluated 66 patients with high-degree
carotid artery stenosis (degree of asymptomatic vs. symp-
tomatic stenosis 87.8 7.8% vs. 87.5 10.2%). Out of this
group, we obtained suitable plaque specimens of 18
symptomatic and 15 asymptomatic patients for histological
and eight symptomatic and nine asymptomatic patients for
immunohistochemical analysis. No differences were found
between clinical variables, risk factor profiles and phar-
macological treatment among the study groups (Table 2).
Serum assessment of PAPP-A
To determine whether the abundant expression of PAPP-A
in unstable plaques might correspond with the elevated
circulating levels of this biomarker, we measured PAPP-A
levels in patients with high-degree asymptomatic and
symptomatic carotid artery stenosis.
Mean PAPP-A serum levels in patients with clinically
asymptomatic CS (nZ 29) were 0.11 mgml e
(SD 0.05 mg ml1). Patients with symptomatic stenosis
(nZ 37) showed significantly lower PAPP-A serum values of
0.07 mgml1 (SD 0.09 mgml1, pZ 0.025). Following
adjustment for age, gender and degree of stenosis, the
differences between the groups remained statistically
significant (pZ 0.050). The coefficient of the linear
regression model changed only minimally from 0.405 to
0.391. All three factors used for adjustment contributed
equally to the result. Analysing plaque stability and PAPP-A
expression patients with unstable and ruptured plaques
(nZ 24) showed significantly increased serum concentra-
tions of PAPP-A compared with patients with stable plaques
(nZ 20, 0.112 0.06 mg ml1 vs. 0.074 0.04 mg ml1,
pZ 0.047) (Fig. 1).
Subgroup analysis of serological values of PAPP-A still
demonstrates that serological PAPP-A values in symptomatic
patients were significantly higher in unstable carotid lesions:
0.54 (0.34e1.30) for unstable versus 0.39 (0.24e0.91) for
stable lesions (pZ 0.035). No differences were, however,
observed in the subgroup analysis of asymptomatic patients:
1.16 (0.49e1.89) versus 1.09 (0.45e1.85) (pZ 0.791).Immunohistochemical localisation of PAPP-A
Immunohistochemistry with CD68 and PAPP-A antibody
showed positive results in plaques of both asymptomatic
Table 2 Patient characteristics: Hypertension includes any treated or untreated pathological blood pressure, Diabetes
mellitus includes any treated IDDM or NIDDM, Hypercholesterolemia is defined as >240 mg/ml, Renal disease is defined as
a glomerular filtration rate of <70 ml/min, Coronary heart disease is defined according to the Canadian Class Classification
>CCS II.
Asymptomatic Symptomatic Total p-Value
Patients 29 (43.9) 37 (56.1) 66 0.676d
Maleb 21 (72.4) 25 (67.6) 46
Femaleb 8 (27.6) 12 (32.4) 20
Age (years)a 67.9 8.2 68.1 8.6 67.9 8.4 0.816d
Risk factorsa 2.4 1.1 2.4 1.0 2.4 1.1 0.842d
Hypertension b 25 (86.2) 32 (86.5) 57 (86.4) 0.751d
Diabetes mellitus b 6 (20.7) 7 (18.9) 13 (19.7) 0.903d
Hypercholesterolemiab 23 (79.3) 28 (75.7) 51 (77.3) 0.883d
Tobacco useb 11 (37.9) 20 (54.1) 31 (47.0) 0.162d
Renal diseaseb 4 (13.8) 3 (8.1) 7 (10.6) 0.499d
CHDb 10 (34.5) 10 (27.3) 20 (30.3) 0.570d
Medication
Thrombocyte aggregation
inhibitorsb
28 (96.6) 36 (97.3) 64 (96.9) 0.326d
Beta-Blockersb 19 (65.5) 23 (62.2) 42 (63.6) 0.893d
ACE-Inhibitorsb 16 (55.2) 16 (43.2) 32 (48.5) 0.398d
Statinsb 16 (55.2) 20 (54.1) 36 (54.6) 0.976d
Vasodilatatorsb 5 (17.2) 0 5 (7.6) 0.023d
Degree of Stenosis (%)a 87.8 7.8 87.5 10.2 87.6 9.1 0.751c
Peak systolic
velocity (cm/s)a
377.7 151.6 341.5 163.9 358.3 158.0 0.536c
a Data given as mean SD.
b Data are numbers of patients unless otherwise indicated, number in parentheses are percentages.
c P Value obtained with ManneWhitney U Test.
d P-Value obtained with Chi-Square-Test.
PAPP-A and Carotid Plaque Activity 671and symptomatic patients. Enhanced expression of PAPP-A
was associated with macrophage foam cells (CD68 posi-
tive), especially in cap and shoulder region of the plaques
(Fig. 2). Focussing on the expression of PAPP-A in athero-
matous plaques and CD68-positive cells, a significant
correlation was observed (nZ 17, correlation coefficient
rZ 0.291, p< 0.001). Mean occurrence of foam cells in
stable plaques was 1.4% of the whole plaque area and 2.4%
in unstable plaques.Figure 1 Serological concentration of PAPP-A in patients in co
neurological symptomatology (b, nZ 66).In asymptomatic patients macrophage-associated PAPP-
A expression was detected in 57.1% of stable plaques and in
95.0% of unstable plaques. Focussing on the symptomatic
group, 28.5% of the stable plaques showed expression of
PAPP-A; in unstable plaques it was detected in 68.9%
(Fig. 3).
A positive correlation between PAPP-A expression in
histological specimens and PAPP-A serum concentration
was observed (nZ 17, correlation coefficient rZ 0.618,rrelation to plaque stability (a, nZ 33) as well as to clinical
Figure 3 Overview of expression of PAPP-A in carotid artery
plaques. Therefore plaques of 17 patients were evaluated. In
each plaque four consecutive cross sections within the area of
highest degree of lumen stenosis were analysed histologically.
672 P. Heider et al.p< 0.008) (Fig. 4). Furthermore, PAPP-A expression in
plaques correlated significantly with the cap thickness,
leading to reduction of the fibrous cap and increase of
PAPP-A expression (correlation coefficient rZ0.639,
p< 0.001) (Fig. 5).
ROC analysis was performed to examine the perfor-
mance of PAPP-A expression as well as the symptomatology
by plotting the fraction of true positives rate against false-
positive rate (Fig. 6). Cut-off values for asymptomatic and
symptomatic stenosis as well as plaque stability were
determined by using the Youden index (JZmaximum
{sensitivityþ specificity 1}) based on ROC curves (Table
3). The cut-off values of PAPP-A were as follows: patients
with serum levels higher than 0.395 mgml1 were classified
as symptomatic (positive predictive value) (Fig. 6(a)),
patients with PAPP-A lower than 0.555 mgml1 were
considered as asymptomatic (Fig. 6(b)).
Discussion
Disruption of carotid atherosclerotic plaque and subse-
quent embolisation of debris is a common pathogenic
mechanism for cerebral ischaemia. Plaque vulnerability is
associated with an increased number of inflammatory cells
at the atheromatous site.8 Activation of macrophages leads
to the secretion of various metalloproteinases, which cause
a weakening of plaque tissue and eventually leads to plaque
rupture.9 PAPP-A is a high-molecular-weight zinc-binding
matrix metalloproteinase and was originally identified in
the plasma of pregnant women.10e12 Vascular endothelial
and smooth muscle cells are responsible for production and
secretion of PAPP-A within atherosclerotic plaques.3 PAPP-
A is a local regulator of insulin-like growth factor-1 (IGF-1)
activity and may thus promote the proatherogenic effects
of IGF-1. Up-regulation of PAPP-A in unstable plaques
suggests that the involvement of the PAPP-A system may be
clinically relevant.13e15 Despite the results of Dominguez16
demonstrating that circulating PAPP-A levels does not
sufficiently detect acute myocardial infarction (AMI) caused
by plaque disruption, our results demonstrate a significant
correlation of PAPP-A with the instability of carotid
plaques.16Figure 2 Immunostaining of carotid artery plaque with CD68 an
expresison of PAPP-A. Macrophage foam-cells (CD-68 positive) wer
necrotic core, (B) macrophages, foam cells (immunostaining for CD
macrophages, (D) fibrous area (collagen, proteoglycans), (E) endotMetalloproteinases have already been associated with
macrophage-rich shoulder regions of atherosclerotic lesions
and implicated in plaque rupture.17,18 In our study, we
confirmed that PAPP-A is expressed by activated macro-
phages especially in fibrous caps and that expression of
PAPP-A was associated with macrophages. Although the
correlation was weak, we found a similar localisation in
almost all specimens on immunohistological staining (see
also Fig. 2). Therefore, the relatively weak correlation in
our study might be due to the limitation of our analysing
method.
Bayes-Genis found that PAPP-A was expressed in both
eroded and ruptured plaques but was only minimally
expressed in stable plaques of patients with cardiac
disease.3 Similarly, Elseber observed significantly higher
serum PAPP-A levels in patients with unstable angina or
acute myocardial infarction than in control subjects.19
Based on these results, it was suggested that increased
plasma levels of PAPP-A reflect the instability ofd PAPP-A to detect correlation of macrophage foam-cells and
e found around the plaque shoulder and in the fibrous cap. (A)
68), (B1) immunostainig for PAPP-A positive macrophages, (C)
helium, (F) vessel lumen.
Figure 4 Graph showing correlation between serum values
of PAPP-A (mg/ml) versus expression of PAPP-A in histological
slices (correlation coefficient rZ 0.618, p< 0.008). Therefore
we measured areas of dense expression of PAPP-A-positive
cells in relation to total cross section area. Data are calcu-
lated as areas of PAPP-expression e plaque area e ratio (% of
Plaque area in mm2).
PAPP-A and Carotid Plaque Activity 673atherosclerotic plaques and that PAPP-A might be a specific
marker of acute coronary syndromes.20 However, Cosin-
Sales indicated that even in patients with stable coronary
heart disease, PAPP-A levels are associated with morpho-
logical plaque complexity and predict recurrence of symp-
toms in patients with ACS.4 Therefore, we compared serum
PAPP-A levels in patients with neurologically asymptomatic
and symptomatic CS with histopathological findings to
evaluate the prognostic significance of PAPP-A with regard
to destabilisation of atherosclerotic plaques. In accordance
with Sangiorgi, we demonstrated that unstable plaques are
present in both asymptomatic and symptomatic patients.Figure 5 Correlation of thickness of fibrous cap and
expression of PAPP-A in macrophages was evaluated in 68 cross
sections of 17 patients. p-value< 0.001; rZ0.639 (non-
parametric measurement of correlation by Spearman).Furthermore plaque stability correlated significantly with
expression of PAPP-A within the carotid lesions in our
study.21 Moreover, we could demonstrate a correlation
between the serological concentration of PAPP-A and its
expression in plaques as well as a correlation between
expression of PAPP-A in plaques and thickness of fibrous
caps.
Elevated oxidative stress is believed to play an impor-
tant role in plaque destabilisation. Previous studies
demonstrated a high proteolytic activity of PAPP-A when it
is not bound in a covalent complex with the proform of
eosinophil major basic protein (proMBP).11,22 This is
a reason for the detection of PAPP-A in the blood secreted
by atherosclerotic plaques. High uncomplexed amounts of
circulating PAPP-A could be a marker of oxidative stress.
Stulc and Miedema described that serum PAPP-A levels
were significantly higher in patients with severe hyper-
cholesterolemia than in healthy normolipidaemic control
subjects, despite the absence of clinically manifest
atherosclerosis.20,23 This suggests that an increase in PAPP-
A may reflect earlier stages of atherosclerotic lesions, even
in the absence of clinical signs of atherosclerosis. We
demonstrated a correlation between a decrease of fibrous
cap thickness and expression of PAPP-A. Particularly in
asymptomatic patients, we detected a group of patients
with rupture-prone plaques and high levels of PAPP-A. In
our opinion, these results demonstrate highly active plaque
formations in a clinically still silent situation. However, the
interpretation of increased PAPP-A levels is difficult. The
values reported to date for patients with acute coronary
syndrome differ substantially and a threshold value for
unstable plaques or preclinical atherosclerosis still does not
exist and needs careful evaluation.
In contrary to recent studies, we found higher circu-
lating levels of PAPP-A in clinically asymptomatic CS. We
hypothesise that we measured free and membrane-bound
PAPP-A with high proteolytic activity, while symptomatic
CA has internalised PAPP-A with little or no protease
activity.24 Qin reported that only the free form of PAPP-A is
relevant in such patients.25 Harrington already found that
loss of PAPP-A has a predominant effect on lesion
progression rather than lesion initiation.26 In our opinion,
a high circulating level of PAPP-A is a sign of developing
‘juvenile’ unstable plaques. Given its proteolytic potential
and the associations between concentrations and athero-
sclerotic plaques, PAPP-A may contribute to the degrada-
tion of a plaque’s extracellular matrix.27
Previous studies with PAPP-A in cardiovascular disease
showed a sensitivity of 89% and specificity of 79%.28 In our
study, we achieved an adequate sensitivity and specificity
with a promising positive predictive value to determine
plaque instability accurately. We believe that disruption of
carotid plaques releases PAPP-A to the circulation in the
early phase before severe clinical neurological symptoms
appear. In our opinion, it makes PAPP-A an interesting
biomarker for the detection of rupture-prone plaques and
an impending neurological event, especially in patients
with asymptomatic carotid artery stenosis. However, more
prospective studies in carotid artery patients are required
to evaluate the exact mechanism by which PAPP-A
promotes atherogenesis as well as to validate its utility in
diagnosis and therapeutic guidance.
Figure 6 a: ROC curves for comparison of the performance of the expression of PAPP-A in serum vs. instability of the carotid
plaque; b: expression of PAPP-A in serum vs. clinical neurological status (asymptomatic patient) of the patient. The curve above
the diagonal shows the true-positive against the false-negative rate for determination of possible cut-off values of a prediction
algorithm as a trade-off between sensitivity and specificity. The greater the AUC (area under curve), the more accurate is the
model.
674 P. Heider et al.Study Limitations
Despite careful and detailed data analysis, our study has
some limitations. First, we cannot exclude the possibility
that the PAPP-A level in blood of the study patients could
originate from other unstable plaques than carotid. It is,
however, known that most cardiovascular events are
caused by thrombotic occlusion of a single plaque and not
multiple plaque rupture.29 Therefore, we assumed that the
increased PAPP-A level was caused by the unstable carotid
lesion. However, we cannot completely exclude the possi-
bility that, in some patients, the increase of PAPP-A could
also have other reasons. Second, in contrast to the study of
Sangiorgi, our data demonstrated an overall increased
PAPP-A level in asymptomatic patients. The reason for this
discrepancy could be that we only measured free PAPP-A in
blood. It is, however, known that upon activation and
inflammatory reaction, two PAPP-A forms, complexed and
uncomplexed with proMBP, can be found and this PAPP-A is
not recognised by the assay we have used in our study.
Thus, the lower level of PAPP-A in the symptomatic patients
may be only due to the less free PAPP-A.Table 3 Combined sensitivity, specificity and positive
predictive value (PPV) for optimal cut-off pointsa (plaque
stability in histological specimen and neurological symp-
toms). PAPP-A was measured in serum (mg/ml).
Cut-off
point
Sensitivity
(%)
Specificity
(%)
PPV
Plaque stability 0.395 100 62.5 68.8
Neurological
symptomatology
0.555 82.8 35.3 73.7
a The optimal decision rule (cut-off point) for prediction of
neurological symptoms was determined by using Youden index
(JZmaximum {sensitivityþ specificity 1}) for each factor.Conclusion
The present study provides evidence that circulating levels
of PAPP-A are associated with an enhanced inflammatory
state and a shift from stable to unstable carotid artery
disease. Plaque rupture is a common cause of stroke and
our results suggest that circulating PAPP-A levels might be
an early marker of the processes leading to plaque insta-
bility and rupture. Nevertheless, using concentrations of
circulating PAPP-A for the diagnosis of rupture-prone
carotid lesions still needs careful consideration. Further
tests with larger studies are needed to prove the relevance
of PAPP-A as a prognostic marker for the presence of
vulnerable plaques and its role in stroke prevention.
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